{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-010792","form_type":"8-K","ticker":null,"cik":"0001261249","company_name":"AGILE THERAPEUTICS INC","filed_at":"2023-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.215824+00:00","generated_at":"2026-06-14T07:11:11.209094+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Agile Therapeutics gets Nasdaq extension to Sept 25, 2023; must meet $2.5M equity rule","bullets":["Received 180-day extension from Nasdaq; must regain compliance with $2.5M stockholders' equity by Sept 25, 2023.","Reported stockholders' equity of ($5.545M) as of Dec 31, 2022, below requirement.","Failure to demonstrate compliance by Sept 25 may lead to delisting; company intends to take measures.","Delisting could reduce liquidity, market price, and access to equity markets."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-010792","json":"https://secwatch.observer/filing/0001558370-23-010792.json","markdown":"https://secwatch.observer/filing/0001558370-23-010792.md","text":"https://secwatch.observer/filing/0001558370-23-010792.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1261249/000155837023010792/0001558370-23-010792-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1261249/000155837023010792/agrx-20230602x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T07:11:11.209094+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ef23a2d2f1fe29e203848893670f9eea0cea62a9","claim":"AGILE THERAPEUTICS INC received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"(the “Stockholders’ Equity Requirement”). The Company’s Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2022, reported stockholders’ equity of $(5,545,000), which is below the Stockholders’ Equity Requirement for continued listing on the Nasdaq Capital Market. The Company submitted a plan to regain compliance with the Stockholders’","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1261249/000155837023010792/0001558370-23-010792-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}